Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report

J Antimicrob Chemother. 2019 Nov 1;74(11):3399-3401. doi: 10.1093/jac/dkz318.

Authors

Collaborators

IMAGES Group:
Vincenzo Pisani, Chiara Costa, Giuseppe Greco, Valentina La Gamba, Aida Giancotti, Giorgio Settimo Barreca, Cinzia Peronace, Ovidia La Valle, Giuseppina Cimino, Paola La Torre, Antonio Gemelli, Francesco Antonio Tropea, Francesco Picicco

Affiliations

¹ Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, 'Magna Graecia' University, Catanzaro, Italy.
² Unit of Clinical Microbiology, Department of Health Sciences, 'Magna Graecia' University, Catanzaro, Italy.
³ Unit of Intensive Care, Department of Medical and Surgical Sciences, 'Magna Graecia' University, Catanzaro, Italy.

PMID: 31369095
DOI: 10.1093/jac/dkz318

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acinetobacter Infections / blood
Acinetobacter Infections / drug therapy*
Acinetobacter baumannii / drug effects
Adult
Anti-Bacterial Agents / therapeutic use*
Cefiderocol
Cephalosporins / therapeutic use*
Compassionate Use Trials
Critical Illness / therapy
Drug Resistance, Multiple, Bacterial*
Humans
Influenza, Human / complications
Influenza, Human / microbiology
Klebsiella Infections / blood
Klebsiella Infections / drug therapy*
Klebsiella pneumoniae / drug effects
Microbial Sensitivity Tests
Pneumonia / complications
Pneumonia / virology
Treatment Outcome

Substances

Anti-Bacterial Agents
Cephalosporins